GSK and Hansoh Pharma have entered into an exclusive license agreement for HS-20093, a B7-H3 targeted ADC utilising a clinically validated topoisomerase inhibitor payload.
GSK and Hansoh Pharma, a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders, today announced that they have entered into an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug…